Features Associated with Therapy Switch Among PPD CorEvitas Psoriasis Registry Patients

Area of Science:

• Dermatology
• Pharmacology
• Real-world evidence studies

Background:

• Psoriasis treatment often requires switching biologic therapies when initial treatments fail.
• Identifying predictors of switching can optimize patient care and satisfaction.

Purpose of the Study:

• To identify real-world baseline features associated with switching biologic therapies in psoriasis patients.
• To understand factors influencing treatment changes after sustained biologic use.

Main Methods:

• Retrospective analysis of the Psoriasis Registry cohort.
• Utilized logistic regression, random forest, and decision trees.
• Assessed sociodemographics, comorbidities, disease activity, and patient-reported outcomes.

Main Results:

• 6.8% of follow-up visits involved a biologic switch.
• Key predictors included baseline body surface area (BSA) involvement, change in BSA, and addition of non-biologic systemic medications.
• Patient-reported fatigue and quality of life also emerged as important factors.

Conclusions:

• Specific patient subgroups with moderate/severe BSA involvement and other factors show a high likelihood of switching.
• Recognizing these features aids clinician-patient shared decision-making.
• Improved decision-making can enhance outcomes and satisfaction with psoriasis biologic therapy.